85 min listen
Christopher J. Moreau: DMT, Neuroplasticity & Stroke Recovery | Episode 200
Christopher J. Moreau: DMT, Neuroplasticity & Stroke Recovery | Episode 200
ratings:
Length:
45 minutes
Released:
Dec 7, 2022
Format:
Podcast episode
Description
Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company's board of directors. With over 30 years of executive management experience overall, including 15 years in CEO roles, he has proven achievements in operations management, acquisitions, licensing, and integration.Algernon Pharmaceuticals plans to be the first Company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible this year. DMT is a "classic" psychedelic compound part of the tryptamine family.https://algernonpharmaceuticals.com
Released:
Dec 7, 2022
Format:
Podcast episode
Titles in the series (100)
NFX #2: Finding Passion in Medicine w/ Karl Wallenkampf by NeuroFlex Podcast